Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.7.12.2 (
MEK
)
18,161
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Norcantharidin (NCTD), a demethylated analog of cantharidin derived from Chinese traditional medicine blister beetle, has been currently used as an anticancer drug for various cancers including hepatocellular carcinoma (HCC). In this study, for a more comprehensive understanding of the targets of NCTD in HCC, next-generation RNA-Seq was utilized. We revealed that the expression of
FAM46C
, which has been reported as a tumor suppressor for multiple myeloma, was enhanced after NCTD treatment. Re-analysis of TCGA (The Cancer Genome Atlas) LIHC (liver hepatocellular carcinoma) dataset demonstrated that
FAM46C
expression was significantly lower in HCC tissues than in normal liver tissues. NCTD injection or
FAM46C
overexpression could mitigate diethylnitrosamine (DEN)-initiated HCC in mice. Ectopic expression of
FAM46C
in two HCC cell lines, SMCC-7721 and SK-Hep-1, significantly repressed cell proliferation, and increased cells population in G2/M phase and cell apoptotic rate. We also found that
FAM46C
overexpression caused a notable decrease in Ras expression,
MEK1
/2 phosphorylation and ERK1/2 phosphorylation. More importantly,
FAM46C
knockdown significantly weakened the biological effects of NCTD on HCC cells, which suggested NCTD exerted the anticancer functions partially through up-regulating
FAM46C
. In conclusion,
FAM46C
, a tumor suppressor for HCC, is important for the anti-proliferation and proapoptotic effects of NCTD.
...
PMID:FAM46C is critical for the anti-proliferation and pro-apoptotic effects of norcantharidin in hepatocellular carcinoma cells. 2923 37